# Study of CYR-101 in Patients With Schizophrenia

> **NCT00861796** · PHASE2 · COMPLETED · sponsor: **Cyrenaic Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** CYR-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00861796
- **Lead sponsor:** Cyrenaic Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861796, "Study of CYR-101 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00861796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*